Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient

E. Cofrancesco, C. Boschetti, M. A. Viviani, C. Bargiggia, A. M. Tortorano, M. Cortellaro, C. Zanussi

Research output: Contribution to journalArticlepeer-review


We recently succeeded in eradicating a Fusarium infection by treatment with liposomal amphotericin B (L-AmB). The patient, a 22-year-old man with acute lymphoblast leukaemia (ALL), developed fever and diffuse cutaneous maculopapular necrotising nodules during post-chemotherapy neutropenia. Fusarium verticilloides was isolated from the skin, and hyphae were observed on direct microscopy. Despite increased WBC and amphotericin B (AmB) treatment (0.7 mg/kg/day for 11 days), he remained febrile and a chest X-ray revealed pulmonary lesions. Fusarium infection was confirmed by bronchial aspirate. AmB was increased to 1 mg/kg/day, and continued for 16 days (total dose 1630 mg). A slight improvement was observed at tomography, but nephrotoxicity developed. Treatment was changed to L-AmB (3 mg/kg/day). The patient received this drug for 20 days (total dose of 3850 mg) with complete regression of the pulmonary lesions. No adverse event occurred, and nephrotoxicity resolved. The patient was discharged from hospital cured of the Fusarium infection and in clinical and haematological remission. No relapse of fusariosis occurred, despite additional courses of intensive chemotherapy. Ambisome could represent an important advance in antifungal treatment since it allows aggressive treatment and eradication of mycoses refractory to conventional therapy while avoiding renal toxicity.

Original languageEnglish
Pages (from-to)280-283
Number of pages4
Issue number3
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Efficacy of liposomal amphotericin B (AmBISOME) in the eradication of Fusarium infection in a leukaemic patient'. Together they form a unique fingerprint.

Cite this